Showing BioInteractions for Foreskin fibroblast (neonatal) (DB10770)
BioInteractor utilizes data on drug-target, -enzyme and -transporter associations to provide insight on drug-drug interactions. It allows you to identify, for instance, which drugs act similarly on the same target. Such drugs may have additive pharmacodynamic effects if given concomitantly. Conversely, two drugs may antagonize the beneficial effects of each other by having opposite actions on a specific drug target. BioInteractor uses ranked drug-enzyme association information to predict enzyme-mediated drug interactions that may be clinically relevant.
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Interleukin-6 agonist | ||
| 1 | Interleukin-6 antagonists | Ginseng, Siltuximab |
| 2 | Interleukin-6 inhibitors | Polaprezinc |
| 3 | Interleukin-6 agonists | Foreskin keratinocyte (neonatal) |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Vascular endothelial growth factor receptor 1 agonist | ||
| 1 | Vascular endothelial growth factor receptor 1 inhibitors | Axitinib, Fostamatinib, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Selpercatinib, Sorafenib, Sunitinib |
| 2 | Vascular endothelial growth factor receptor 1 agonists | Polaprezinc |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Interleukin-1 receptor type 1 agonist | ||
| 1 | Interleukin-1 receptor type 1 antagonists | Anakinra |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a TGF-beta receptor type-2 agonist | ||
| 1 | TGF-beta receptor type-2 agonists | Foreskin keratinocyte (neonatal) |
| 2 | TGF-beta receptor type-2 inhibitors | Fostamatinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Fibroblast growth factor 1 agonist | ||
| 1 | Fibroblast growth factor 1 antagonists | Pentosan polysulfate |
| 2 | Fibroblast growth factor 1 inhibitors | Amlexanox, Pazopanib |
| 3 | Fibroblast growth factor 1 agonists | Foreskin keratinocyte (neonatal) |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Interferon gamma agonist | ||
| 1 | Interferon gamma agonists | Foreskin keratinocyte (neonatal) |
| 2 | Interferon gamma neutralizers | Emapalumab |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Fibroblast growth factor receptor 2 agonist | ||
| 1 | Fibroblast growth factor receptor 2 agonists | Foreskin keratinocyte (neonatal), Palifermin |
| 2 | Fibroblast growth factor receptor 2 binders | Palifermin |
| 3 | Fibroblast growth factor receptor 2 antagonists | Thalidomide |
| 4 | Fibroblast growth factor receptor 2 inhibitors | Erdafitinib, Fostamatinib, Lenvatinib, Nintedanib, Pemigatinib, Ponatinib, Pralsetinib, Regorafenib, Selpercatinib |
| 5 | Fibroblast growth factor receptor 2 ligands | Sucrosofate |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Granulocyte-macrophage colony-stimulating factor receptor subunit alpha agonist | ||
| 1 | Granulocyte-macrophage colony-stimulating factor receptor subunit alpha agonists | Foreskin keratinocyte (neonatal), Sargramostim |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Platelet-derived growth factor receptor beta agonist | ||
| 1 | Platelet-derived growth factor receptor beta antagonists | Dasatinib, Imatinib, Midostaurin, Sorafenib, Trapidil |
| 2 | Platelet-derived growth factor receptor beta inhibitors | Fostamatinib, Midostaurin, Nintedanib, Pazopanib, Pexidartinib, Pralsetinib, Regorafenib, Ripretinib, Sunitinib |
| 3 | Platelet-derived growth factor receptor beta agonists | Polaprezinc |
| 4 | Platelet-derived growth factor receptor beta substrates | Erdafitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Transforming growth factor beta-1 agonist | ||
| 1 | Transforming growth factor beta-1 inhibitors | Hyaluronidase, Hyaluronidase (human recombinant), Hyaluronidase (ovine) |
| 2 | Transforming growth factor beta-1 agonists | Foreskin keratinocyte (neonatal) |
| 3 | Transforming growth factor beta-1 inducers | Terazosin |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin fibroblast (neonatal) is a Tumor necrosis factor agonist | ||
| 1 | Tumor necrosis factor inhibitors | Amrinone, Chloroquine, Infliximab, Polaprezinc, Pomalidomide, Pseudoephedrine, Thalidomide |
| 2 | Tumor necrosis factor neutralizers | Certolizumab pegol |
| 3 | Tumor necrosis factor antagonists | Epinephrine, Glycyrrhizic acid |
| 4 | Tumor necrosis factor agonists | Epinephrine, Foreskin keratinocyte (neonatal) |
| 5 | Tumor necrosis factor inducers | Bryostatin 1 |